Business
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025. To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant websit
About this update from Roivant Sciences Ltd.
[{"type":"image","alt":"Immunovant Inc.","displaySize":"","headline":null,"caption":"Immunovant Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":32,"url":"https://media.zenfs.com/en/globenewswire.com/d82fe53a8399bc9c522ea1269d40b006"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PQ86vzFPuLGg8eDjozRmNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTU4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d82fe53a8399bc9c522ea1269d40b006","width":200,"height":32}},"lazy":false},{"type":"text","content":"NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.","length":252,"tagName":"p"},{"type":"text","content":"To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.","length":407,"tagName":"p"},{"type":"text","content":"About Immunovant Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.","length":396,"tagName":"p"},{"type":"text","content":"Contacts:InvestorsKeyur [email protected]","length":57,"tagName":"p"},{"type":"text","content":"MediaStephanie [email protected]","length":45,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]